3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
273
Carcinoma, Non-Small-Cell Lung
224
Prostatic Neoplasms
181
Neoplasms
174
Lung Neoplasms
137
Multiple Myeloma
136
Neoplasm Metastasis
101
Colorectal Neoplasms
100
Melanoma
87
Ovarian Neoplasms
80
Leukemia, Myeloid, Acute
74
Pancreatic Neoplasms
73
Lymphoma
69
Carcinoma, Renal Cell
65
Leukemia, Lymphocytic, Chronic, B-Cell
64
Brain Neoplasms
63
Lymphoma, Non-Hodgkin
62
Squamous Cell Carcinoma of Head and Neck
61
Recurrence
56
Urinary Bladder Neoplasms
55
Hematologic Neoplasms
55
Carcinoma, Hepatocellular
54
Head and Neck Neoplasms
53
Triple Negative Breast Neoplasms
51
Lymphoma, Follicular
48
Glioblastoma
48
Endometrial Neoplasms
47
Uterine Cervical Neoplasms
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Sarcoma
44
Interventions
pertuzumab
1
Trastuzumab
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Advanced HER2+Breast Cancer
×
90 days
×
Clear all
NCT04208178
2026-04-02
EPIK-B2
Novartis
Phase 3
Active not recruiting
19 enrolled